CLDI net incomeQ2 2026-$4.16M
CLDI net income was -$4.16M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.71M a year earlier. For the full fiscal 2025 it was -$19.91M, compared with -$22.14M in fiscal 2024.
Calidi Biotherapeutics Inc. (CLDI) financials
For the twelve months ended Jun 30, 2026, Calidi Biotherapeutics Inc. reported -$17.47M of net income.
- Net income, TTM
- -$17.47M
- Cash
- $4.29M
- Total debt
- $600.0K
- Market cap
- $2.5M
FY2022FY2025
CLDI revenue and earnings growth
CLDI EPSQ2 2026-$2.94
CLDI diluted EPS was -$2.94 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$5.95.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | - | - | - | $45.0K |
| Research and development | $9.74M | $8.88M | $13.01M | $7.26M |
| Selling, general and admin | $10.50M | $12.90M | $15.98M | $15.90M |
| Operating income | -$20.24M | -$21.78M | -$28.99M | -$23.13M |
| Pre-tax income | -$20.05M | -$22.20M | -$29.20M | -$25.42M |
| Income tax | $15.0K | $14.0K | $16.0K | $11.0K |
| Net income | -$19.91M | -$22.14M | -$29.22M | -$25.43M |
| EPS, basic | -$5.95 | -$35.70 | -$17.33 | $2.99 |
| EPS, diluted | -$5.95 | -$35.70 | -$17.33 | $2.99 |
| Diluted shares | 4,302 | 667 | 1.7M | 8.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $5.82M | $9.81M | $2.17M | $590.0K |
| Receivables | - | - | - | $870 |
| Current assets | $6.26M | $10.23M | $4.30M | $786.0K |
| Total assets | $8.86M | $14.18M | $10.02M | $2.60M |
| Current liabilities | $3.94M | $9.50M | $10.23M | $42.99M |
| Short-term debt | $90.0K | $3.22M | $807.0K | $5.42M |
| Total debt | $600.0K | $600.0K | $2.06M | - |
| Total liabilities | $5.10M | $12.21M | $18.25M | $43.44M |
| Shareholders' equity | $3.76M | $1.97M | -$8.23M | -$50.44M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$21.29M | -$19.69M | -$26.98M | -$13.21M |
| Investing cash flow | -$170.0K | -$16.0K | -$478.0K | -$494.0K |
| Financing cash flow | $17.46M | $27.36M | $29.04M | $12.09M |
| Stock-based compensation | $2.11M | $2.96M | $4.81M | $4.52M |
| Depreciation and amortization | $1.65M | $1.53M | - | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.56M | $2.59M | $2.36M | $2.36M | $2.59M | $2.42M | $1.81M | $2.15M | $2.17M | $2.74M | $3.96M | $3.25M |
| Selling, general and admin | $1.59M | $1.60M | $2.11M | $2.69M | $3.07M | $2.64M | $2.21M | $3.07M | $3.60M | $4.01M | $5.86M | $3.97M |
| Operating income | -$4.15M | -$4.19M | -$4.47M | -$5.05M | -$5.66M | -$5.06M | -$4.03M | -$5.23M | -$5.77M | -$6.75M | -$9.82M | -$7.22M |
| Pre-tax income | -$4.16M | -$4.10M | -$4.06M | -$5.17M | -$5.76M | -$5.06M | -$4.14M | -$5.07M | -$5.76M | -$7.22M | -$8.23M | -$2.01M |
| Income tax | $5.0K | $4.0K | -$2.0K | $10.0K | $4.0K | $3.0K | $3.0K | -$1.0K | $8.0K | $4.0K | -$3.0K | $11.0K |
| Net income | -$4.16M | -$4.11M | -$4.06M | -$5.15M | -$5.71M | -$5.06M | -$4.10M | -$5.05M | -$5.77M | -$7.22M | -$8.23M | -$2.02M |
| EPS, basic | -$2.94 | -$0.43 | - | -$2.21 | -$31.75 | -$2.21 | - | -$7.75 | -$16.75 | -$2.03 | - | -$1.41 |
| EPS, diluted | -$2.94 | -$0.43 | - | -$2.21 | -$31.75 | -$2.21 | - | -$7.75 | -$16.75 | -$2.03 | - | -$1.41 |
| Diluted shares | 1.4M | 10.3M | - | 4,907 | 180,000 | 2.3M | - | 652 | 444 | 3,555 | - | 1.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.29M | $6.85M | $5.82M | $10.59M | $5.38M | $10.78M | $9.81M | $2.12M | $1.05M | $1.36M | $2.17M | $10.37M |
| Current assets | $5.43M | $7.35M | $6.26M | $11.03M | $6.05M | $11.49M | $10.23M | $2.22M | $1.63M | $1.94M | $4.30M | $11.69M |
| Total assets | $7.20M | $9.59M | $8.86M | $14.03M | $9.35M | $15.06M | $14.18M | $6.66M | $6.43M | $7.41M | $10.02M | $18.59M |
| Current liabilities | $3.24M | $3.84M | $3.94M | $5.19M | $5.35M | $5.43M | $9.50M | $11.58M | $13.05M | $14.95M | $10.23M | $10.87M |
| Short-term debt | $45.0K | $23.0K | $90.0K | $472.0K | $820.0K | $1.16M | $3.22M | $3.11M | $2.98M | $4.24M | $807.0K | $3.35M |
| Long-term debt | - | - | - | - | - | - | - | $1.77M | $1.93M | $3.38M | - | - |
| Total debt | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $4.88M | $4.91M | $7.61M | $2.06M | $1.95M |
| Total liabilities | $4.07M | $4.66M | $5.10M | $6.83M | $7.28M | $7.76M | $12.21M | $16.45M | $18.18M | $21.98M | $18.25M | $19.68M |
| Shareholders' equity | $3.13M | $4.93M | $3.76M | $6.92M | $2.08M | $7.30M | $1.97M | -$9.80M | -$11.75M | -$14.57M | -$8.23M | -$1.09M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.35M | -$4.12M | -$5.04M | -$4.24M | -$4.88M | -$7.13M | -$5.42M | -$4.95M | -$5.49M | -$3.83M | -$5.19M | -$13.52M |
| Investing cash flow | -$33.0K | -$5.0K | -$79.0K | -$27.0K | -$57.0K | -$7.0K | -$5.0K | -$6.0K | $0 | -$5.0K | -$35.0K | -$63.0K |
| Financing cash flow | $1.83M | $5.16M | $340.0K | $9.48M | -$469.0K | $8.11M | $13.11M | $6.05M | $5.20M | $3.01M | -$2.96M | $21.64M |
| Stock-based compensation | $157.0K | $231.0K | $450.0K | $529.0K | $522.0K | $607.0K | $626.0K | $692.0K | $751.0K | $888.0K | $1.19M | $1.11M |
| Depreciation and amortization | $438.0K | $426.0K | $423.0K | $427.0K | $407.0K | $394.0K | $393.0K | $390.0K | - | - | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.68 | 1.92 | 1.59 | 2.12 | 1.13 | 2.12 | 1.08 | 0.19 | 0.12 | 0.13 | 0.42 | 1.07 |
| Debt to equity | 0.19 | 0.12 | 0.16 | 0.09 | 0.29 | 0.08 | 0.30 | - | - | - | - | - |
Source: XBRL data Calidi Biotherapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CLDI peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CLDI | - | - | -$17.47M | - | $2.5M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $248.84B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.84B |
| MRNA | $2.23B | -27.6% | -$3.15B | -141.4% | $96.40B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $55.53B |
| RVMD | $0 | - | -$1.13B | - | $38.08B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.06B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.57B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.77B |
CLDI FAQ
4 questionsIs CLDI profitable?
No. Calidi Biotherapeutics Inc. reported a net loss of $17.47M for the twelve months ended Jun 30, 2026.How much cash and debt does CLDI have?
Calidi Biotherapeutics Inc. reported $4.29M in cash and cash equivalents and $600.0K of debt on its most recent balance sheet in SEC filings.When did CLDI last report financial results?
The latest statements here come from Calidi Biotherapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this CLDI financial data come from?
Quantisnow builds these statements from the structured XBRL data Calidi Biotherapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.